AbbVie signs $2.54 billion potential oncology collaboration with DISCO Pharmaceuticals for AND-gated bispecifics

AbbVie will combine its oncology development expertise with DISCO's tumour-surface mapping technology to discover selective bispecific therapies, with $40 million payable upfront and further potential milestones.
On 19 November 2026, DISCO Pharmaceuticals announced a research collaboration and option-to-license agreement with AbbVie to discover AND-gated bispecific therapeutics targeting solid tumours, including $40 million in upfront payments.
DISCO may receive up to $2.5 billion in additional option, development and other milestone payments plus tiered royalties, while AbbVie can elect to license selected programmes following specified research activities.
Field | Content |
Alert Type | Deal |
Companies | AbbVie; DISCO Pharmaceuticals |
Deal Type | Strategic research collaboration and option-to-license agreement |
Asset or Company | Investigational AND-gated bispecific therapeutics discovered using DISCOtech |
Therapy Area(s) | Oncology; solid tumours |
Technology or Modality | DISCOtech surfaceome mapping and AND-gated bispecific antibody discovery targeting pairs of tumour-associated cell-surface proteins |
Deal Value | $40 million upfront; up to $2.5 billion in additional contingent option, development and other milestone payments; tiered royalties on worldwide net sales. Approximately $2.54 billion in potential upfront and milestone consideration excluding royalties. |
Geography | Germany and United States; potential worldwide commercialisation |
What Happened | DISCO Pharmaceuticals entered a research collaboration with AbbVie to identify tumour-selective antigen pairs and discover AND-gated bispecific therapeutics. AbbVie may obtain exclusive licences to selected programmes after specified research activities. |
Why It Matters | The agreement supports development of investigational therapies designed to recognise combinations of tumour-associated surface proteins rather than relying on a single target, potentially improving selectivity. |
Supporting Context | DISCOtech maps tumour-cell surface protein expression to identify pairs suitable for simultaneous recognition. The approach is intended to distinguish tumour cells from healthy tissue displaying only one of the targets. |
Strategic Rationale | The collaboration combines DISCO's surfaceome mapping and bispecific discovery platform with AbbVie's oncology research and development capabilities. |
Potential Impact | The partnership could advance new solid-tumour programmes if research identifies suitable targets and development candidates demonstrate acceptable safety and efficacy; clinical benefit remains unproven. |
Key Takeaway | DISCO secures $40 million upfront and potential milestone payments under an oncology discovery collaboration; the headline transaction value is predominantly contingent rather than guaranteed. |
What to Watch | Completion of research activities, AbbVie's decisions on exclusive licensing options, selection of development candidates and subsequent preclinical or clinical progress. |
Primary Source | https://discopharma.de/disco-pharmaceuticals-announces-strategic-collaboration/ |
Relevant Date | 19 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Comments